Jundishapur Journal of Microbiology

Published by: Kowsar

Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran

Zahra Salehei 1 , Zahra Seifi 1 , * and Ali Mahmoudabadi 1 , 2
Authors Information
1 Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Infectious Diseases and Tropical Medicine Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: September 01, 2012, 5 (4); 574-577
  • Published Online: September 9, 2012
  • Article Type: Research Article
  • Received: February 21, 2012
  • Revised: March 10, 2012
  • Accepted: April 3, 2012
  • DOI: 10.5812/jjm.4556

To Cite: Salehei Z, Seifi Z, Mahmoudabadi A. Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran, Jundishapur J Microbiol. 2012 ;5(4):574-577. doi: 10.5812/jjm.4556.

Abstract
Copyright © 2012, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005; 43(5): 2155-62[DOI][PubMed]
  • 2. Ehrstrom S, Yu A, Rylander E. Glucose in vaginal secretions before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol. 2006; 108(6): 1432-7[DOI]
  • 3. Nyirjesy P, Peyton C, Weitz MV, Mathew L, Culhane JF. Causes of chronic vaginitis: analysis of a prospective database of affected women. Obstet Gynecol. 2006; 108(5): 1185-91[DOI]
  • 4. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses. 2006; 49(6): 471-5[DOI][PubMed]
  • 5. Jilek P, Spacek J, Buchta V, Kucera Z, Drahosova M, Forstl M, et al. [Systemic immunity in patients with recurrent vulvovaginal candidiasis]. Ceska Gynekol. 2005; 70(6): 453-9[PubMed]
  • 6. Aali BS, Tohidi A. Prevalence of Candida vaginitis among symptomatic patients in Kerman. J Qazvin Uni Med Sci. 2000; 13: 42-8
  • 7. Aghamirian M, Jahani Hashemi H. Agents associated with candida vulvovaginitis in women referred to health centers in Qazvin. J Qazvin Uni Med Sci. 2007; 11(3): 35-9
  • 8. Jamilian M, Mashadi E, Sarmadi F, Ghaznavi A, Bani Jamali M, Farhadi E, et al. Frequency of vulvovaginal candidiasis species in non-pregnant 15-50 years old women in spring 2005 in Arak. J Arak Uni Med Sci. 2007; 2(10): 7-14
  • 9. Khoursandi M, Modares GM, Khosravi A. Recovery and Recurrence of Vaginal Candidiasis after oral and Intravaginal Treatment. J Qazvin Uni Med Sci. 2000; 14(25): 2
  • 10. Ramezan Zadeh F, Babaei GR, Fakhar F. A survey of oral contraceptive pills (LD) as a cause of Candidial vaginitis. Hakim Res J. 2001; 1(4): 25-30
  • 11. Kamali F, Gharibi T, Naiemi B, Afshary P. Treatment of candida vaginitis: comparison of single and sequential dose of fluconazole. Iranian South Med J. 2003; 6(1): 25-30
  • 12. Kariman NS, Shafaei Z, Afrakhteh M, Valaei N, Ahmadi M. Comparing fluconazole and clotrimazole in treatment of Candida albicans vaginiti. Behbood. 2002; 14(6): 9-16
  • 13. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res. 2007; 126(3): 216-9[PubMed]
  • 14. Momeni A, Shadzi S, Ghadeganipour M, Asilian A, Khorsandi R. The effect of itraconazole on treatment of vaginal candidiasis. J Kerman Uni Med Sci. 1995; 2(2): 71-7
  • 15. Ramezan Zadeh F, Babaei GR, Karbalaei Mohammad S. Comparative study of efficacy of single-dose (500mg) and three days (200mg daily) treatment of candidial vulvovaginitis by vaginal tablets of Clotrimazole. Hakim Res J. 2000; 2(3): 103-8
  • 16. Consolaro ME, Albertoni TA, Svidzinski AE, Peralta RM, Svidzinski TI. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia. 2005; 159(4): 501-7[DOI][PubMed]
  • 17. Mahmoudabadi AZ, Najafyan M, Alidadi M. Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci. 2010; 26(3): 607-10
  • 18. Pakshir K, Bahaedinie L, Rezaei Z, Sodaifi M, Zomorodian K. In vitro activity of six antifungal drugs against clinically important dermatophytes. Jundishapur J Microbiol. 2007; 2(4): 158-63
  • 19. Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL, et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006; 44(10): 3578-82[DOI][PubMed]
  • 20. Defontaine A, Bouchara JP, Declerk P, Planchenault C, Chabasse D, Hallet JN. In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. J Med Microbiol. 1999; 48(7): 663-70[DOI][PubMed]
  • 21. Al-Abeid HM, Abu-Elteen KH, Elkarmi AZ, Hamad MA. Isolation and characterization of Candida spp. in Jordanian cancer patients: prevalence, pathogenic determinants, and antifungal sensitivity. Jpn J Infect Dis. 2004; 57(6): 279-84[PubMed]
  • 22. Quindos G, Abarca L, Carrillo-Munoz AJ, Arevalo MP, Bornay FJ, Casals JB, et al. Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. Rev Iberoam Micol. 1999; 16(2): 97-100[PubMed]
  • 23. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol. 2000; 38(4): 1563-8[PubMed]
  • 24. Gianni C. Update on antifungal therapy with terbinafine. G Ital Dermatol Venereol. 2010; 145(3): 415-24[PubMed]
  • 25. Barot BS, Parejiya PB, Patel HK, Gohel MC, Shelat PK. Microemulsion-based gel of terbinafine for the treatment of onychomycosis: optimization of formulation using D-optimal design. AAPS Pharm Sci Tech. 2012; 13(1): 184-92[DOI][PubMed]
  • 26. Shivakumar V, Okade R, Rajkumar V, Sajitha K, Prasad SR. Intermittent pulse-dosed terbinafine in the treatment of tinea corporis and/or tinea cruris. Indian J Dermatol. 2011; 56(1): 121-2[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments